OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825
| Autor: | Renke Zhou, Terri S. Armstrong, Michael E. Scheurer, Stephanie L. Pugh, Ying Yuan, Melissa Bondy, E.P. Sulman, Mark R. Gilbert, Elizabeth Vera, Merideth Wendland |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Temozolomide Leukopenia Bevacizumab Karnofsky Performance Status business.industry O-6-methylguanine-DNA methyltransferase medicine.disease ORAL PRESENTATIONS Risk model Internal medicine medicine In patient Neurology (clinical) medicine.symptom business medicine.drug Glioblastoma |
| Zdroj: | Neuro-Oncology. 19:iii10-iii10 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/nox036.033 |
| Popis: | BACKGROUND: Myelotoxicity is a rare but serious side effect of TMZ. In RTOG0825, 16% and 23% of patients experienced grade 3 or higher myelotoxicity during chemoradiation or adjuvant phase, respectively. Our goal was to evaluate risk and validate prediction of myelotoxicity in patients treated with TMZ +/- bevacizumab (BEV). METHODS: Clinical characteristics (including age, height, weight, gender, race/ethnicity, concurrent medications, baseline laboratory studies, performance status, and tumor characteristics) as well as severe TMZ-related myelotoxicity (CTCAE version 3.0 for grade 3 and higher leukopenia, neutropenia and/or thrombocytopenia) were extracted from the RTOG 0825 database. First, a risk prediction model of myelotoxicity was built including only clinical factors; second, that model was extended using the single nucleotide polymorphisms (SNPs) identified by a genome-wide association study (GWAS). We also conducted a joint effects analysis to test the hypothesized dose-response relationship between genotype and myelotoxicity, by summing the number of at-risk alleles of the top SNPs identified from the main effect analysis. Results: There were 134 cases and 457 controls. Receiving BEV with TMZ increased myelotoxicity risk 80% (odds ratio OR=1.82; 95% confidence interval [CI], 1.02–3.27; adjusted p= 0.04). Females were approximately 4.5 times more likely to develop toxicity (OR=4.45; 95% CI, 2.45–8.08; adjusted p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|